Who is sponsoring NCT00002663?

NCT00002663 is sponsored by Atara Biotherapeutics.

What drugs are being tested in NCT00002663?

Interventions in NCT00002663: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs).

What condition does NCT00002663 study?

NCT00002663 studies EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma.

Is NCT00002663 still recruiting?

NCT00002663 is currently completed. Last updated 18 January 2023.

Are results published for NCT00002663?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-01-18 · How we verify

NCT00002663

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases

Completed Phase 1/Phase 2 Results posted Last updated 18 January 2023

What this trial tests

Phase 1/Phase 2 trial testing Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) in EBV-induced Lymphomas in 58 participants. Completed in 1 July 2019.

Timeline

1 March 1995

Primary endpoint
1 July 2019

1 July 2019

Quick facts

Lead sponsor	Atara Biotherapeutics
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	1 March 1995
Primary completion	1 July 2019
Estimated completion	1 July 2019
Sites	1 location across United States

Drugs / interventions tested

Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) — full drug profile →

Conditions studied

EBV-induced Lymphomas — all drugs for EBV-induced Lymphomas →
EBV-associated Malignancies — all drugs for EBV-associated Malignancies →
Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma — all drugs for Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma →

Sponsor

Atara Biotherapeutics — full company profile →

Who can join

Eligibility, any sex, with EBV-induced Lymphomas or EBV-associated Malignancies. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective Response Rate (ORR)
Time frame: From Day 1 through 251.1 months after Day 1 dose
The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when i

Sponsor's own description

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
Prockop S, Doubrovina E, Suser S, Heller G, et al · · 2020 · cited 190× · PMID 31689242 · DOI 10.1172/jci121127
Novel Immunotherapies for T Cell Lymphoma and Leukemia.
Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, et al · · 2018 · cited 27× · PMID 30317410 · DOI 10.1007/s11899-018-0480-8
Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
Grant ML, Bollard CM. · · 2018 · cited 22× · PMID 29198753 · DOI 10.1016/j.blre.2017.11.004
Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.
Markouli M, Ullah F, Omar N, Apostolopoulou A, et al · · 2022 · cited 18× · PMID 36497432 · DOI 10.3390/cancers14235949
Cells to prevent/treat relapse following allogeneic stem cell transplantation.
Dietz AC, Wayne AS. · · 2017 · cited 10× · PMID 29222325 · DOI 10.1182/asheducation-2017.1.708
Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
Bender Ignacio RA, Lin LL, Rajdev L, Chiao E. · · 2018 · cited 9× · PMID 30099376 · DOI 10.6004/jnccn.2018.7064
Developing T-cell therapies for lymphoma without receptor engineering.
Grant M, Bollard CM. · · 2017 · cited 6× · PMID 29296911 · DOI 10.1182/bloodadvances.2017009886
Adoptive Cell Immunotherapy in Relapse/Refractory Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorders.
Canichella M, de Fabritiis P. · · 2025 · cited 2× · PMID 40558101 · DOI 10.3390/antib14020047

Verify or expand the search:

Other Atara Biotherapeutics trials

Trials by the same sponsor.

NCT06429800 — A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus · Phase 1 · withdrawn
NCT06256484 — A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-H · Phase 1 · terminated
NCT03769467 — Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma · Phase 1, PHASE2 · terminated
NCT03283826 — Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis · Phase 1, PHASE2 · terminated
NCT02822495 — Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002663 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atara Biotherapeutics
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing